Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Altimmune, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
3.24
10.7
10.3
5.8
8.19
4.41
-0.07
0.43
0.02
0.04
Research and development
7.22
18.4
18.5
17.8
49.8
74.5
70.5
65.8
82.2
66.4
General and administrative
7.11
8.46
9.77
8.5
13.2
15.4
17.1
18.1
21
28.1
Operating expenses
14.3
62.8
53.2
27.3
63
101
87.7
96.4
103
94.5
Operating income
-11.1
-52
-42.8
-21.5
-54.8
-96.9
-87.7
-95.9
-103
-94.5
Interest expense
0.04
0.16
0.3
0
0.01
0.01
0.01
0.04
0.01
1.64
Interest income
0
0.05
0.23
0.84
0.32
0.2
2.87
7.35
8.07
7.54
Other non-operating income
0
-0.02
-2.49
0.89
0.34
-0.18
2.83
7.48
8.11
5.72
Pre-tax income
-11.1
-52.1
-45.3
-20.6
-54.5
-97.1
-84.9
-88.4
-95.1
-88.8
Income tax
0
-5.64
-6.15
-0.06
-5.42
-0.2
-0.68
Net income
-11.1
-46.4
-39.2
-20.5
-49
-97.1
-84.7
-88.4
-95.1
-88.1
EBITDA
-11
-52
-42.6
-21.1
-54.4
-96.4
-87.9
-95.5
-103
-94.4
EPS, basic
2.97
-118.91
-15.16
-1.60
-1.91
-2.35
-1.81
-1.66
-1.34
-1.00
EPS, diluted
2.95
-118.91
-15.16
-1.60
-1.91
-2.35
-1.81
-1.66
-1.34
-1.00
Shares, basic (weighted)
65.3
0.43
2.8
13.1
25.6
41.3
46.9
53.2
71
88.1
Shares, diluted (weighted)
65.7
0.43
2.8
13.1
25.6
41.3
46.9
53.2
71
88.1
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
2.88
8.77
33.7
8.96
116
190
111
135
36.9
43.8
Short-term investments
66.8
28.3
100
73.8
62.7
95
230
Other current assets
0.42
0.99
0.55
0.47
1.93
7.95
5.36
6.92
2.2
2.96
Total current assets
4.49
23.5
39.4
39.4
230
204
193
210
137
278
Property, plant and equipment
0.18
0.6
1.34
1.1
1.06
1.45
1.08
0.65
0.41
0.31
Lease right-of-use assets
0.7
0.9
0.8
0.6
0.36
1.64
1.43
Goodwill
18.8
0
0
Intangible assets
15
38.7
13.9
12.7
12.8
12.4
12.4
0
0
Other non-current assets
0.02
0.24
0.18
0.13
0.98
0.87
0.62
0.36
1.64
1.43
Total assets
38.4
63
54.8
54.1
245
219
207
211
139
280
Accounts payable
2.01
0.13
0.37
0.02
0.61
2.03
4.8
2.07
0.21
2.72
Accrued liabilities
2.97
3.66
4.08
3.9
11.4
2.31
2.96
3.32
3.08
4.68
Deferred revenue
0.02
0.02
0.02
0.06
0.02
Total current liabilities
5.47
3.84
4.53
3.92
12
18.3
17.1
12.1
10.5
15
Long-term debt
1.85
1.86
1.83
1.45
4.58
34.3
Lease liabilities
1.48
1.47
1.12
0.67
0.18
1.4
1.15
Other non-current liabilities
0.44
0.16
0.14
0.13
0.11
0.08
0.06
0.04
5.33
5.75
Total liabilities
6.19
14.4
6.44
8.54
19.2
19.7
21.6
16.5
15.8
55
Total debt
0.53
0.6
0.57
1.86
1.83
1.45
4.58
34.3
Paid-in capital
71
122
170
188
417
497
568
665
690
879
Retained earnings
-31.3
-77.7
-117
-137
-186
-293
-378
-466
-561
-649
Other comprehensive income
-7.57
-4.58
-5.04
-5.02
-5.04
-5.04
-5.23
-5
-4.97
-4.93
Shareholders' equity
32.2
39.4
48.3
45.5
226
199
185
194
124
225
Total equity
32.2
39.4
48.3
45.5
226
199
185
194
124
225
Total liabilities and equity
38.4
63
54.8
54.1
245
219
207
211
139
280
Shares outstanding
6.92
0.61
9.08
15.3
37.1
41
49.2
70.7
72.4
111
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-11.1
-46.4
-39.2
-20.5
-49
-97.1
-84.7
-88.4
-95.1
-88.1
Depreciation and amortization
0.06
0.08
0.22
0.39
0.43
0.55
-0.21
0.48
0.24
0.11
Stock-based compensation
0.97
1.44
0.77
1.26
2.58
5.52
8.1
10.6
14.4
16.1
Deferred income tax
0.06
-2.62
-6.15
-0.06
-0.68
Change in receivables
0.13
-1.95
0.34
2.44
-3.59
4.18
0.26
-0.94
0.57
-0.68
Change in payables
0.85
-2.62
0.24
-0.35
0.59
1.42
2.77
-2.73
-1.86
2.51
Cash from operations
-6.35
-20.2
-9.39
-9.6
-34.3
-78.2
-62.6
-75.8
-79.8
-67.5
Capital expenditures
-0.12
-0.11
-0.98
-0
-0.2
-12.1
-0.13
-0.05
-0.01
Purchases of investments
-28.3
-128
-7.59
-73.3
-88.6
-116
-285
Cash from investing
-0.22
13.7
-1
-28.3
-72.2
87.5
-73.4
13.7
-28.4
-132
Debt issued
0
35
Stock issued
3.8
0.02
4.33
48.2
64.8
56.2
86.6
9.99
174
Cash from financing
4.98
15.8
32.5
12.5
213
65.1
56.8
86.1
10
207
Exchange rate effect
-0.17
0.07
-0.05
Net change in cash
138
9.43
22
-25.4
107
74.4
-79.2
24
-98.2
6.83
Free cash flow
-6.48
-20.3
-10.4
-9.6
-34.5
-90.4
-62.7
-75.9
-67.5
Interest paid
0
0.01
0.06
0
0.98
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.06 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-19.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-17.4%
Net income / average total assets.
Return on invested capital (ROIC)
-17.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
105.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 5y
-65.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
82.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
6.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-0.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
100.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
10.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
2.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
24.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
23.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
28.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
26.8x
Current assets / current liabilities.
Quick ratio
26.1x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
26.1x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.07x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
6.6%
Total debt / total assets.
Liabilities / assets
10.1%
Total liabilities / total assets.
Net debt
-$291.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.41
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.41
Cash from operations / diluted weighted shares.
Book value per share
$2.44
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.26x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.26x
Market cap / tangible book value, when positive.
FCF yield
-12.9%
Free cash flow / market cap.
Earnings yield
-15.4%
Net income / market cap (the inverse of P/E).
What was Altimmune, Inc.'s revenue in fiscal 2025?
Altimmune, Inc. reported revenue of $41.0K for fiscal 2025, 105% higher than the year before.
Was Altimmune, Inc. profitable in fiscal 2025?
No. It reported a net loss of $88.1M.
How much free cash flow did Altimmune, Inc. generate in fiscal 2025?
Cash from operations of $67.5M minus capital expenditures of $11.0K left free cash flow of -$67.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.